Statins, a primary class of lipid-lowering drugs, occupy an irreplaceable position in the field of cardiovascular medicine (Vinci et al., 2021; Cardiovascular disease, 2023). This class of drugs blocks the synthesis of cholesterol in the liver by specifically inhibiting the activity of a key enzyme, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (Sirtori, 2014; Liu et al., 2019). This mechanism not only significantly reduces levels of total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB) and triglycerides (TG) in the blood (Liu et al., 2019; Oesterle et al., 2017), but also offers long-term benefits in promoting vascular health and preventing atherosclerosis (Cai et al., 2021).

As the incidence of cardiovascular diseases continues to rise globally, the clinical demand for statins is also increasing. It is reported that the market share of statin drugs worldwide is continuously expanding, even formulating a trend of “statinization” globally (Blais et al., 2021). The commonly used statin drugs in clinical practice include atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin. Cerivastatin was withdrawn from the market in 2001 due to the serious adverse event of rhabdomyolysis. Correspondingly, adverse events associated with statin use have been continuously reported, including statin-associated muscle symptoms (SAMS) (Vinci et al., 2021; Thompson et al., 2016), diabetes mellitus (DM) (Thompson et al., 2016), and neurocognitive disorders (Xiao et al., 2024).

Active liver disease is a contraindications for the use of statins. Currently, numerous studies have analyzed the influence of statins on liver-related diseases, with some suggesting that statin use is significantly associated with liver disease protection and may be beneficial in the treatment of liver diseases (Vell et al., 2023). However, Liang X et al.’s study clearly indicated that statins increase the risk of liver damage (Liang et al., 2018). Therefore, it is very necessary to conduct further analysis of the hepatotoxicity of statins in this study.

The purpose of this study was to conduct an in-depth analysis of real-world data from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database to investigate hepatic disorders caused by statin drugs, thereby contributing to a deeper understanding of their safety. In addition, the results of the study will provide certain reference information for clinical drug use, and help clinicians better weigh the benefits and risks of statins, thereby further optimizing treatment plans and maximizing the therapeutic effect.

Statins are a cornerstone of lipid-lowering therapy and cardiovascular treatment. As their clinical applications continue to expand, researchers are gradually revealing the multiple efficiencies of this class of drugs. In addition to their core function of lowering cholesterol levels, statins have been shown to have antioxidant, endothelial-protective, and anti-inflammatory effects (Liu et al., 2019; Mollazadeh et al., 2021; Koushki et al., 2021) Furthermore, statins may also have the potential to reduce the risk of certain cancers (Jiang et al., 2021; Santoni et al., 2022) and improve the prognosis for patients with chronic kidney disease (Zhao et al., 2021). Recent research also suggests that statins may offer significant health benefits in patients with chronic liver disease and cirrhosis (Vargas et al., 2017).

The study of Montastruc JL demonstrated that statins may cause serious adverse reactions such as rhabdomyolysis, which warned us that the potential risks of statins should not be ignored (Montastruc, 2023). As the metabolic center of statins, the safety of the liver is particularly worth concerning. Current studies have pointed out that the use of statin drugs may lead to an abnormal increase in liver enzyme levels without symptoms, but these studies have not been deeply explored. When studying the impact of atorvastatin on the liver, Zhang H et al. found that the risk of hepatotoxicity may increase by 1.3–1.5 times after using the drug (Zhang et al., 2019). In addition, there have been reports of potential liver adverse reactions that may occur following the use of fluvastatin and simvastatin (Alanazi et al., 2021; Björnsson, 2017). Therefore, this study is of significant practical importance and necessity.

This study found that statins-induced hepatic disorders showed no significant difference between males and females, predominantly occurring in individuals aged 65–85 years, likely due to the clinical indications of statins for cardiovascular diseases, which are more prevalent in this age group. Additionally, it was observed that statins have a relatively high safety profile and do not lead to a high fatality rate, which could contribute to their widespread use. It was particularly important to note that the fatality rate due to hepatic disorder caused by simvastatin was the highest among the seven statins involved in this study, consistent with the findings of Björnsson ES, who pointed out that there was a certain correlation between simvastatin-induced hepatotoxicity and death (Björnsson, 2017). Mikiewicz M. et al. also found that simvastatin may lead to abnormal glycogen and lipid metabolism, changes in cell membrane permeability, liver fibrosis, hepatitis, decreased liver cell function, and an increased risk of apoptosis (Mikiewicz et al., 2019). Therefore, these findings serve as a warning that when using simvastatin, liver conditions of patients should be closely monitored to enhance clinical safety. It is worth noting that atorvastatin had the highest number of hepatic disorder cases, the highest number of annual reports, and the highest number of PTs of hepatic disorder events in this study. Simvastatin and rosuvastatin also showed relatively higher numbers which may be related to their significant lipid-lowering efficacy, leading to their extensive clinical use (Zhang et al., 2020).

Among the various hepatic disorders reported, autoimmune hepatitis and drug-induced liver injury have emerged as notable signals. For instance, autoimmune antibodies such as anti-nuclear antibody (ANA) and anti-smooth muscle antibody (ASMA) may appear following the use of rosuvastatin (Sánchez et al., 2018). The use of simvastatin has been associated with changes in hepatocytes resembling autoimmune hepatitis, accompanied by the emergence of antinuclear antibodies (Mikiewicz et al., 2019). There have also been reports of positive ANA and anti-ribonucleoprotein (RNP) antibodies following the use of atorvastatin (Tse et al., 2023). Additionally, it is particularly noteworthy that the signal value for autoimmune hepatitis induced by fluvastatin use is relatively high. This finding is consistent with the observation of fluvastatin induced autoimmune hepatitis in clinical practice by Nakayama and Murashima (2011). These studies not only suggest that statins should be used cautiously in patients with autoimmune diseases, but also provided a basis for future in-depth research on the relationship between statins and immune response. At the same time, it also suggests that clinicians should strengthen the monitoring of patients’ immune function after the use of statins, and actively search for possible immune-related answers.

The significant signal strength in cholestatic pruritus and bilirubin conjugation abnormal indicates a potential for severe hepatic reactions. In past medical research, statin drugs have been proven to be associated with cholestatic pruritus (Averbukh et al., 2022). Li WK et al. shed light on how statins affect the metabolic processes of bile acids. They found that atorvastatin, a widely used statin, significantly affects the expression of a key rate-limiting enzyme CYP7A1 in the liver (Li et al., 2017), which plays a crucial role in the synthesis of bile acids. By increasing the expression of CYP7A1, atorvastatin is able to promote bile acid synthesis, which may be responsible for cholestasis and related symptoms. A clinical review study further provided a detailed description of the pattern of liver damage caused by statins (Averbukh et al., 2022). Clinicians should pay close attention to the potential bile secretion disorders caused by statins. Before prescribing statins, physicians should perform a baseline liver function assessment to ensure the patient is free of liver disease and suitable for statin treatment. It is equally important to regularly monitor patients’ liver function during treatment to make informed and rational treatment decisions.

This study utilized the FAERS database to conduct a systematic analysis of the hepatotoxicity of statin drugs. On the one hand, we identified potential adverse events of hepatic disorder that may be caused by statin drugs. On the other hand, we conducted a thorough investigation of adverse events with specific signals. This study provided valuable insights into the potential hepatotoxicity of statins and added a new theoretical basis for evaluating the safety of these widely used drugs. Additionally, our study pointed the way for future pharmacovigilance analyses and clinical trials, aiding in further validating our findings and elucidating the mechanisms behind hepatotoxicity. However, we must also acknowledge that this study has certain limitations. Firstly, since the FAERS database relies on spontaneous reporting, there may be issues with underreporting and misreporting, which means that the information in the database may not entirely reflect the full picture of adverse events that occur after the actual use of statin drugs. Secondly, the causal relationship between the identified adverse events and statin drugs has not been definitively confirmed. Thirdly, this study did not adequately control for the disease background and concurrent drug situations of the subjects included in the study, which are confounding factors. Therefore, the accurate assessment of the hepatotoxicity of statins requires more prospective studies for in-depth analysis and clinical validation.

This study highlights the potential hepatotoxicity issues associated with statin drugs, particularly noting the high incidence rates of atorvastatin, simvastatin, and rosuvastatin, with fluvastatin exhibiting a particularly prominent overall signal value for hepatotoxicity. In addition, adverse reactions such as autoimmune hepatitis and drug-induced liver injury that may occur during statin use also pose potential safety risks. Particularly, the specific adverse reactions of cholestatic pruritus and bilirubin conjugation abnormal caused by statins deserve further attention.